Enliven Therapeutics, Inc.
ELVN evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $4.21B
- Lead Asset:
- elvn-001 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for ELVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELVN
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision therapies, with its lead candidate relcobatinib (ELVN-001) in Phase 3 for chronic myeloid leukemia after FDA alignment on trial design [news · 2026-10-06].
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for Enliven Therapeutics, Inc..
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision therapies, with its lead candidate relcobatinib (ELVN-001) in Phase 3 for chronic myeloid leukemia after FDA alignment on trial design [news · 2026-10-06].
- Cash & equivalents of $135.5M as of 2026-06-30 [sec].
- Net income of -$32.5M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $895.1M as of 2026-06-30 [sec].
- FDA alignment reached on ENABLE-2 Phase 3 trial design for relcobatinib (ELVN-001) in previously treated CML [news · 2026-10-06].
- Company is exploring strategic alternatives for ELVN-002 and no longer pursuing its development [sec_mda · as of 2026-03-03].
What works
- FDA alignment on Phase 3 trial design for lead candidate ELVN-001 de-risks the pivotal regulatory pathway [news · 2026-10-06].
- Positive updated clinical data from the Phase 1b ENABLE trial presented at EHA 2025 and updated in January 2026 [sec_mda · as of 2026-03-03].
- Cash position of $135.5M as of 2026-06-30 provides runway to advance the BCR-ABL program through clinical development [sec].
What to weigh
- Company has no approved products and expects net losses to continue for the foreseeable future [sec_mda · as of 2026-08-05].
- Expenses and capital requirements are expected to increase substantially as clinical development advances [sec_mda · as of 2026-08-05].
- ELVN-002 program is being deprioritized, reducing pipeline diversification [sec_mda · as of 2026-03-03].
From the filings
Quoted directly from source documents.
Net losses expected to continue
“Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on a variety of factors including the timing and scope of our research and development activities.”
SEC MD&A · August 5, 2026
ELVN-002 program deprioritized
“we are exploring strategic alternatives for the ELVN-002 program and are no longer pursuing its development.”
SEC MD&A · March 3, 2026
Catalyst timeline
- 2022-05-22 · Phase 1 start for ELVN-001 (CML) — Initiated Phase 1a/1b study of ELVN-001 for chronic myeloid leukemia.
- 2023-03-20 · Phase 1 start for ELVN-002 (HER2 mutant NSCLC) — Initiated Phase 1a/1b study of ELVN-002 for HER2 mutant non-small cell lung cancer.
- 2024-05-30 · Phase 1 start for ELVN-002 combination studies — Initiated Phase 1a/1b studies of ELVN-002 combined with trastuzumab in HER2+ solid tumors and colorectal/breast cancer.
- 2025-01-23 · Phase 1 start for ELVN-001 in Japanese participants — Initiated Phase 1 study of ELVN-001 in Japanese participants with CML with/without T315I mutation.
Risks & what to watch (3)›
Key risks
- No approved products — Company has no marketed products and relies solely on clinical-stage candidates [sec_mda · as of 2026-03-03].
- Increasing expenses — Expenses expected to rise substantially as clinical programs advance, potentially straining cash runway [sec_mda · as of 2026-08-05].
- Pipeline concentration — Deprioritization of ELVN-002 leaves pipeline heavily dependent on ELVN-001 success [sec_mda · as of 2026-03-03].
What to watch
- Initiation and enrollment of the ENABLE-2 Phase 3 trial for ELVN-001 following FDA alignment [news · 2026-10-06].
- Cash burn rate and any additional capital raises under the $200M shelf registration [sec_mda · as of 2026-08-05].
- Outcome of strategic alternatives for the ELVN-002 program [sec_mda · as of 2026-03-03].
Sources: Catalysts · News · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Enliven Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Enliven Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.02 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
0 buys · 38 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
171
Total value held
$2.45B
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 7,959,538 | $312.0M |
| fmr llc | 6,829,246 | $267.7M |
| polar capital holdings plc | 5,065,933 | $198.6M |
| blackrock, inc. | 3,684,707 | $144.4M |
| commodore capital lp | 3,275,000 | $128.4M |
| vestal point capital, lp | 3,250,000 | $127.4M |
| bellevue group ag | 2,320,867 | $91.0M |
| vanguard capital management llc | 2,168,162 | $85.0M |
| fairmount funds management llc | 1,855,644 | $72.7M |
| citadel advisors llc | 1,743,915 | $68.4M |
Showing top 10 of 171 institutional holders of Enliven Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 12.8%
- Days to cover
- 3.0
- Shares short
- 5,374,014
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELVN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Enliven Therapeutics, Inc.?
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision therapies, with its lead candidate relcobatinib (ELVN-001) in Phase 3 for chronic myeloid leukemia after FDA alignment on trial design [news · 2026-10-06].
What is Enliven Therapeutics, Inc.'s lead drug candidate?
Enliven Therapeutics, Inc.'s most advanced tracked candidate is elvn-001 (Phase 1) for CML (Chronic Myelogenous Leukemia); Chronic Myeloid Leukemia.
Who is the CEO of Enliven Therapeutics, Inc.?
Mr. Richard A. Fair M.B.A. is the chief executive officer of Enliven Therapeutics, Inc. (ELVN).
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc. (ELVN) is headquartered in Boulder, CO, United States.
What therapeutic areas does Enliven Therapeutics, Inc. focus on?
Enliven Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.